Study for the effects of once-daily semaglutid on glycemic control in patients with type 2 diabetes (SWITCH SEMA-2 study)
Completed
- Conditions
- type 2 diabetes
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 172
Inclusion Criteria
- Age 20-90 years old
- HbA1c 7.0-10.0%
- BMI >= 18.5 kg/m2
- patients who were treated with DPP-4 inhibitors at least for 12 weeks without discontinuation for more than 1 week (SItagliptin, teneligliptin, and anagliptin: from regular dose to maximun dose; vildagliptin, saxagliptin, trelagliptin, linagliptin, alogliptin, and omarigliptin: regular dose)
- written informed consent
Exclusion Criteria
- treatment with GLP-1 receptor agonists within past 12 weeks
- history of anaphylaxis of semaglutide
- unstable retinopathy
- severe hepatic dysfunction or renal dysfunction
- severe ketosis, diabetic coma
- severe infection, surgery, serious trauma
- female patients who are pregnant, lactating and/or willing to be pregnant, or male patients who wants to impregnate partner during study period
- patients who are inadequate to enter this study due to the other reasons by physician's judgments
Study & Design
- Study Type
- Interventional
- Study Design
- parallel assignment
- Primary Outcome Measures
Name Time Method - The change in HbA1c at 24 weeks from baseline
- Secondary Outcome Measures
Name Time Method